Follow the people · Insider
Thomas DesRosier
Thomas DesRosier files insider transactions with the SEC as an officer of Seres Therapeutics (MCRB). We hold 3 disclosed purchases and sales filed since 27 May 2008, 1 of them in the last 90 days.
- Files forMCRB
- Disclosed buys and sells3 in all, 1 in the last 90 days
- Last disclosure18 August 2026
Positions held
4 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 1 June 2016 — 17 August 2026Officer · Seres Therapeutics (MCRB)82 Form 4 lines · source: SEC Form 4
- Filed 18 February 2015 — 7 March 2016EVP, General Counsel · Ariad Pharmaceuticals (ARIA)7 Form 4 lines · source: SEC Form 4
- Filed 15 April 2013 — 21 January 2015EVP, Chief Legal · Cubist Pharmaceuticals (CBST)27 Form 4 lines · source: SEC Form 4
- Filed 22 May 2008 — 4 April 2011Sr VP, General Counsel · Genzyme (GENZ)31 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 245 shares of Seres TherapeuticsSEC Form 418 August 2026Common Stock · traded 15 August 2026 · filed 18 August 2026
- ▼ sold on the open market 82 shares of Seres TherapeuticsSEC Form 418 August 2026Common Stock · traded 17 August 2026 · filed 18 August 2026
- exercised options over 133 shares of Seres Therapeutics (a derivative holding)SEC Form 418 August 2026Restricted Stock Units · traded 15 August 2026 · filed 18 August 2026
- exercised options over 112 shares of Seres Therapeutics (a derivative holding)SEC Form 418 August 2026Restricted Stock Units · traded 15 August 2026 · filed 18 August 2026
- was granted 7,500 shares of Seres Therapeutics (a derivative holding)SEC Form 410 July 2026Stock Option (right to buy) · traded 8 July 2026 · filed 10 July 2026
- exercised options over 244 shares of Seres TherapeuticsSEC Form 419 May 2026Common Stock · traded 15 May 2026 · filed 19 May 2026
- ▼ sold on the open market 79 shares of Seres TherapeuticsSEC Form 419 May 2026Common Stock · traded 18 May 2026 · filed 19 May 2026
- exercised options over 133 shares of Seres Therapeutics (a derivative holding)SEC Form 419 May 2026Restricted Stock Units · traded 15 May 2026 · filed 19 May 2026
- exercised options over 111 shares of Seres Therapeutics (a derivative holding)SEC Form 419 May 2026Restricted Stock Units · traded 15 May 2026 · filed 19 May 2026
- was granted 22,500 shares of Seres Therapeutics (a derivative holding)SEC Form 46 March 2026Stock Option (right to buy) · traded 4 March 2026 · filed 6 March 2026
- was granted 22,500 shares of Seres Therapeutics (a derivative holding)SEC Form 46 March 2026Stock Option (right to buy) · traded 4 March 2026 · filed 6 March 2026
- exercised options over 244 shares of Seres TherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- ▼ sold on the open market 78 shares of Seres TherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- exercised options over 133 shares of Seres Therapeutics (a derivative holding)SEC Form 418 February 2026Restricted Stock Units · traded 15 February 2026 · filed 18 February 2026
- exercised options over 133 shares of Seres Therapeutics (a derivative holding)SEC Form 418 February 2026Restricted Stock Units · traded 15 February 2026 · filed 18 February 2026
- exercised options over 111 shares of Seres Therapeutics (a derivative holding)SEC Form 418 February 2026Restricted Stock Units · traded 15 February 2026 · filed 18 February 2026
- exercised options over 111 shares of Seres Therapeutics (a derivative holding)SEC Form 418 February 2026Restricted Stock Units · traded 15 February 2026 · filed 18 February 2026
- exercised options over 244 shares of Seres TherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- ▼ sold on the open market 78 shares of Seres TherapeuticsSEC Form 418 February 2026Common Stock · traded 15 February 2026 · filed 18 February 2026
- exercised options over 132 shares of Seres Therapeutics (a derivative holding)SEC Form 418 November 2025Restricted Stock Units · traded 15 November 2025 · filed 18 November 2025
- exercised options over 112 shares of Seres Therapeutics (a derivative holding)SEC Form 418 November 2025Restricted Stock Units · traded 15 November 2025 · filed 18 November 2025
- exercised options over 132 shares of Seres TherapeuticsSEC Form 418 November 2025Common Stock · traded 15 November 2025 · filed 18 November 2025
- exercised options over 112 shares of Seres TherapeuticsSEC Form 418 November 2025Common Stock · traded 15 November 2025 · filed 18 November 2025
- ▼ sold on the open market 76 shares of Seres TherapeuticsSEC Form 418 November 2025Common Stock · traded 15 November 2025 · filed 18 November 2025
- exercised options over 133 shares of Seres Therapeutics (a derivative holding)SEC Form 419 August 2025Restricted Stock Units · traded 15 August 2025 · filed 19 August 2025
- exercised options over 111 shares of Seres Therapeutics (a derivative holding)SEC Form 419 August 2025Restricted Stock Units · traded 15 August 2025 · filed 19 August 2025
- exercised options over 133 shares of Seres TherapeuticsSEC Form 419 August 2025Common Stock · traded 15 August 2025 · filed 19 August 2025
- exercised options over 111 shares of Seres TherapeuticsSEC Form 419 August 2025Common Stock · traded 15 August 2025 · filed 19 August 2025
- ▼ sold on the open market 76 shares of Seres TherapeuticsSEC Form 419 August 2025Common Stock · traded 18 August 2025 · filed 19 August 2025
- exercised options over 133 shares of Seres Therapeutics (a derivative holding)SEC Form 419 May 2025Restricted Stock Units · traded 15 May 2025 · filed 19 May 2025
- exercised options over 111 shares of Seres Therapeutics (a derivative holding)SEC Form 419 May 2025Restricted Stock Units · traded 15 May 2025 · filed 19 May 2025
- exercised options over 133 shares of Seres TherapeuticsSEC Form 419 May 2025Common Stock · traded 15 May 2025 · filed 19 May 2025
- exercised options over 111 shares of Seres TherapeuticsSEC Form 419 May 2025Common Stock · traded 15 May 2025 · filed 19 May 2025
- ▼ sold on the open market 79 shares of Seres TherapeuticsSEC Form 419 May 2025Common Stock · traded 15 May 2025 · filed 19 May 2025
- exercised options over 2,657 shares of Seres Therapeutics (a derivative holding)SEC Form 419 February 2025Restricted Stock Units · traded 15 February 2025 · filed 19 February 2025
- exercised options over 8,907 shares of Seres Therapeutics (a derivative holding)SEC Form 419 February 2025Restricted Stock Units · traded 15 February 2025 · filed 19 February 2025
- exercised options over 2,657 shares of Seres TherapeuticsSEC Form 419 February 2025Common Stock · traded 15 February 2025 · filed 19 February 2025
- exercised options over 8,907 shares of Seres TherapeuticsSEC Form 419 February 2025Common Stock · traded 15 February 2025 · filed 19 February 2025
- ▼ sold on the open market 4,300 shares of Seres TherapeuticsSEC Form 419 February 2025Common Stock · traded 18 February 2025 · filed 19 February 2025
- was granted 650,000 shares of Seres Therapeutics (a derivative holding)SEC Form 411 February 2025Stock Option (Right to Buy) · traded 7 February 2025 · filed 11 February 2025
- exercised options over 2,656 shares of Seres Therapeutics (a derivative holding)SEC Form 419 November 2024Restricted Stock Units · traded 15 November 2024 · filed 19 November 2024
- exercised options over 2,656 shares of Seres TherapeuticsSEC Form 419 November 2024Common Stock · traded 15 November 2024 · filed 19 November 2024
- ▼ sold on the open market 878 shares of Seres TherapeuticsSEC Form 419 November 2024Common Stock · traded 18 November 2024 · filed 19 November 2024
- exercised options over 13,500 shares of Seres Therapeutics (a derivative holding)SEC Form 429 October 2024Restricted Stock Units · traded 27 October 2024 · filed 29 October 2024
- exercised options over 13,500 shares of Seres TherapeuticsSEC Form 429 October 2024Common Stock · traded 27 October 2024 · filed 29 October 2024
- ▼ sold on the open market 4,259 shares of Seres TherapeuticsSEC Form 429 October 2024Common Stock · traded 28 October 2024 · filed 29 October 2024
- exercised options over 2,656 shares of Seres Therapeutics (a derivative holding)SEC Form 419 August 2024Restricted Stock Units · traded 15 August 2024 · filed 19 August 2024
- exercised options over 2,656 shares of Seres TherapeuticsSEC Form 419 August 2024Common Stock · traded 15 August 2024 · filed 19 August 2024
- ▼ sold on the open market 873 shares of Seres TherapeuticsSEC Form 419 August 2024Common Stock · traded 16 August 2024 · filed 19 August 2024
- exercised options over 2,656 shares of Seres Therapeutics (a derivative holding)SEC Form 417 May 2024Restricted Stock Units · traded 15 May 2024 · filed 17 May 2024
- exercised options over 2,656 shares of Seres TherapeuticsSEC Form 417 May 2024Common Stock · traded 15 May 2024 · filed 17 May 2024
- ▼ sold on the open market 843 shares of Seres TherapeuticsSEC Form 417 May 2024Common Stock · traded 15 May 2024 · filed 17 May 2024
- was granted 213,750 shares of Seres Therapeutics (a derivative holding)SEC Form 416 February 2024Stock Option (Right to Buy) · traded 14 February 2024 · filed 16 February 2024
- was granted 287,905 shares of Seres Therapeutics (a derivative holding)SEC Form 416 February 2024Stock Option (Right to Buy) · traded 14 February 2024 · filed 16 February 2024
- was granted 35,625 shares of Seres Therapeutics (a derivative holding)SEC Form 416 February 2024Restricted Stock Units · traded 14 February 2024 · filed 16 February 2024
- exercised options over 10,625 shares of Seres Therapeutics (a derivative holding)SEC Form 416 February 2024Restricted Stock Units · traded 15 February 2024 · filed 16 February 2024
- exercised options over 10,625 shares of Seres TherapeuticsSEC Form 416 February 2024Common Stock · traded 15 February 2024 · filed 16 February 2024
- ▼ sold on the open market 3,939 shares of Seres TherapeuticsSEC Form 416 February 2024Common Stock · traded 16 February 2024 · filed 16 February 2024
- was granted 27,001 shares of Seres Therapeutics (a derivative holding)SEC Form 431 October 2023Restricted Stock Units · traded 27 April 2023 · filed 31 October 2023
- exercised options over 13,501 shares of Seres Therapeutics (a derivative holding)SEC Form 431 October 2023Restricted Stock Units · traded 27 October 2023 · filed 31 October 2023
- exercised options over 13,501 shares of Seres TherapeuticsSEC Form 431 October 2023Common Stock · traded 27 October 2023 · filed 31 October 2023
- ▼ sold on the open market 4,156 shares of Seres TherapeuticsSEC Form 431 October 2023Common Stock · traded 30 October 2023 · filed 31 October 2023
- was granted 42,500 shares of Seres Therapeutics (a derivative holding)SEC Form 47 February 2023Restricted Stock Units · traded 3 February 2023 · filed 7 February 2023
- was granted 85,000 shares of Seres Therapeutics (a derivative holding)SEC Form 47 February 2023Stock Option (Right to Buy) · traded 3 February 2023 · filed 7 February 2023
- was granted 63,492 shares of Seres TherapeuticsSEC Form 46 July 2022COMMON STOCK · traded 5 July 2022 · filed 6 July 2022
- was granted 130,000 shares of Seres Therapeutics (a derivative holding)SEC Form 48 February 2022Stock Option (Right to Buy) · traded 4 February 2022 · filed 8 February 2022
- was granted 100,000 shares of Seres Therapeutics (a derivative holding)SEC Form 48 February 2021Stock Option (Right to Buy) · traded 4 February 2021 · filed 8 February 2021
- was granted 350,000 shares of Seres Therapeutics (a derivative holding)SEC Form 431 January 2020STOCK OPTION (RIGHT TO BUY) · traded 29 January 2020 · filed 31 January 2020
- exercised options over 25,000 shares of Seres Therapeutics (a derivative holding)SEC Form 428 January 2020RESTRICTED STOCK UNITS · traded 26 January 2020 · filed 28 January 2020
- exercised options over 25,000 shares of Seres TherapeuticsSEC Form 428 January 2020COMMON STOCK · traded 26 January 2020 · filed 28 January 2020
- was granted 84,800 shares of Seres Therapeutics (a derivative holding)SEC Form 429 January 2019STOCK OPTION (RIGHT TO BUY) · traded 25 January 2019 · filed 29 January 2019
- exercised options over 15,000 shares of Seres Therapeutics (a derivative holding)SEC Form 429 January 2019RESTRICTED STOCK UNITS · traded 26 January 2019 · filed 29 January 2019
- exercised options over 15,000 shares of Seres TherapeuticsSEC Form 429 January 2019COMMON STOCK · traded 26 January 2019 · filed 29 January 2019
- ▼ sold on the open market 5,471 shares of Seres TherapeuticsSEC Form 429 January 2019COMMON STOCK · traded 28 January 2019 · filed 29 January 2019
- exercised options over 10,000 shares of Seres Therapeutics (a derivative holding)SEC Form 430 January 2018RESTRICTED STOCK UNITS · traded 26 January 2018 · filed 30 January 2018
- was granted 80,000 shares of Seres Therapeutics (a derivative holding)SEC Form 430 January 2018STOCK OPTION (RIGHT TO BUY) · traded 30 January 2018 · filed 30 January 2018
- was granted 100,000 shares of Seres Therapeutics (a derivative holding)SEC Form 430 January 2018STOCK OPTION (RIGHT TO BUY) · traded 30 January 2018 · filed 30 January 2018
- exercised options over 10,000 shares of Seres TherapeuticsSEC Form 430 January 2018COMMON STOCK · traded 26 January 2018 · filed 30 January 2018
- ▼ sold on the open market 3,475 shares of Seres TherapeuticsSEC Form 430 January 2018COMMON STOCK · traded 26 January 2018 · filed 30 January 2018
- was granted 60,000 shares of Seres Therapeutics (a derivative holding)SEC Form 427 January 2017Stock Option (right to buy) · traded 26 January 2017 · filed 27 January 2017
- was granted 50,000 shares of Seres Therapeutics (a derivative holding)SEC Form 427 January 2017Restricted Stock Units · traded 26 January 2017 · filed 27 January 2017
- was granted 100,000 shares of Seres Therapeutics (a derivative holding)SEC Form 42 June 2016Stock Option (right to buy) · traded 1 June 2016 · filed 2 June 2016
- exercised options over 55,000 shares of Ariad PharmaceuticalsSEC Form 430 March 2016Common Stock · traded 18 February 2016 · filed 30 March 2016
- had shares withheld for tax on 18,370 shares of Ariad PharmaceuticalsSEC Form 430 March 2016Common Stock · traded 18 February 2016 · filed 30 March 2016
- exercised options over 55,000 shares of Ariad Pharmaceuticals (a derivative holding)SEC Form 430 March 2016Restricted Stock Units · traded 18 February 2016 · filed 30 March 2016
- was granted 102,500 shares of Ariad Pharmaceuticals (a derivative holding)SEC Form 49 March 2016Employee Stock Option (Right to Buy) · traded 7 March 2016 · filed 9 March 2016
- was granted 30,800 shares of Ariad Pharmaceuticals (a derivative holding)SEC Form 49 March 2016Restricted Stock Units · traded 7 March 2016 · filed 9 March 2016
- was granted 110,000 shares of Ariad Pharmaceuticals (a derivative holding)SEC Form 420 February 2015Restricted Stock Units · traded 18 February 2015 · filed 20 February 2015
- was granted 130,000 shares of Ariad Pharmaceuticals (a derivative holding)SEC Form 420 February 2015Employee Stock Option (Right to Buy) · traded 18 February 2015 · filed 20 February 2015
- acquired or disposed of, other 7,967 shares of Cubist PharmaceuticalsSEC Form 421 January 2015Common Stock · traded 21 January 2015 · filed 21 January 2015
- acquired or disposed of, other 479 shares of Cubist PharmaceuticalsSEC Form 421 January 2015Common Stock · traded 21 January 2015 · filed 21 January 2015
- returned to the issuer 52,232 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 421 January 2015Stock Options (Right to Buy) · traded 21 January 2015 · filed 21 January 2015
- returned to the issuer 7,132 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 421 January 2015Restricted Stock Units · traded 21 January 2015 · filed 21 January 2015
- returned to the issuer 33,433 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 421 January 2015Stock Options (Right to Buy) · traded 21 January 2015 · filed 21 January 2015
- returned to the issuer 4,900 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 421 January 2015Restricted Stock Units · traded 21 January 2015 · filed 21 January 2015
- returned to the issuer 4,356 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 421 January 2015Performance Restricted Stock Units · traded 21 January 2015 · filed 21 January 2015
- acquired or disposed of, other 148 shares of Cubist PharmaceuticalsSEC Form 45 January 2015Common Stock · traded 31 December 2014 · filed 5 January 2015
- exercised options over 17,975 shares of Cubist PharmaceuticalsSEC Form 431 December 2014Common Stock · traded 29 December 2014 · filed 31 December 2014
- had shares withheld for tax on 11,978 shares of Cubist PharmaceuticalsSEC Form 431 December 2014Common Stock · traded 29 December 2014 · filed 31 December 2014
- exercised options over 17,975 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 431 December 2014Stock Options (Right to Buy) · traded 29 December 2014 · filed 31 December 2014
- acquired or disposed of, other 48 shares of Cubist PharmaceuticalsSEC Form 42 October 2014Common Stock · traded 30 September 2014 · filed 2 October 2014
- acquired or disposed of, other 213 shares of Cubist PharmaceuticalsSEC Form 42 July 2014Common Stock · traded 30 June 2014 · filed 2 July 2014
- acquired or disposed of, other 89 shares of Cubist PharmaceuticalsSEC Form 42 July 2014Common Stock · traded 30 June 2014 · filed 2 July 2014
- exercised options over 2,377 shares of Cubist PharmaceuticalsSEC Form 416 April 2014Common Stock · traded 15 April 2014 · filed 16 April 2014
- ▼ sold on the open market 768 shares of Cubist PharmaceuticalsSEC Form 416 April 2014Common Stock · traded 16 April 2014 · filed 16 April 2014
- exercised options over 2,377 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 416 April 2014Restricted Stock Units · traded 15 April 2014 · filed 16 April 2014
- acquired or disposed of, other 84 shares of Cubist PharmaceuticalsSEC Form 42 April 2014Common Stock · traded 31 March 2014 · filed 2 April 2014
- was granted 33,433 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 419 February 2014Stock Options (Right to Buy) · traded 14 February 2014 · filed 19 February 2014
- was granted 4,900 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 419 February 2014Restricted Stock Units · traded 14 February 2014 · filed 19 February 2014
- was granted 4,356 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 419 February 2014Performance Restricted Stock Units · traded 14 February 2014 · filed 19 February 2014
- acquired or disposed of, other 67 shares of Cubist PharmaceuticalsSEC Form 42 January 2014Common Stock · traded 31 December 2013 · filed 2 January 2014
- acquired or disposed of, other 278 shares of Cubist PharmaceuticalsSEC Form 42 January 2014Common Stock · traded 31 December 2014 · filed 2 January 2014
- acquired or disposed of, other 93 shares of Cubist PharmaceuticalsSEC Form 42 October 2013Common Stock · traded 30 September 2013 · filed 2 October 2013
- acquired or disposed of, other 98 shares of Cubist PharmaceuticalsSEC Form 42 July 2013Common Stock · traded 28 June 2013 · filed 2 July 2013
- was granted 70,207 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 416 April 2013Stock Options (Right to Buy) · traded 15 April 2013 · filed 16 April 2013
- was granted 9,509 shares of Cubist Pharmaceuticals (a derivative holding)SEC Form 416 April 2013Restricted Stock Units · traded 15 April 2013 · filed 16 April 2013
- exercised options over 5,542 shares of Genzyme (a derivative holding)SEC Form 46 April 2011Restricted Stock Units · traded 4 April 2011 · filed 6 April 2011
- exercised options over 5,833 shares of Genzyme (a derivative holding)SEC Form 46 April 2011Restricted Stock Units · traded 4 April 2011 · filed 6 April 2011
- returned to the issuer 23,038 shares of Genzyme (a derivative holding)SEC Form 46 April 2011Stock Option (right to buy) · traded 4 April 2011 · filed 6 April 2011
- returned to the issuer 16,625 shares of Genzyme (a derivative holding)SEC Form 46 April 2011Stock Option (right to buy) · traded 4 April 2011 · filed 6 April 2011
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.